Telmisartan

Structure: Non-peptide angiotensin II receptor blocker, selective and insurmountable at the AT1 receptor. It has the highest AT1 affinity and the longest half-life of the ARB class. Uniquely among ARBs it is also a partial agonist at PPAR-gamma, the nuclear receptor targeted by the glitazones, which is where its metabolic effects come from.

Dosage:

• Starting: 20-40mg once daily
• Standard: 40-80mg/day; 80mg is the maximum
• On-cycle blood pressure control: 20-40mg/day is the common range. Titrate to your measured blood pressure, not to a number someone posted on a forum.

Administration:

• Oral, once daily, with or without food
• Full antihypertensive effect takes 4-8 weeks. Do not escalate the dose in week one because nothing happened yet.
• Consistent timing matters; some evidence supports bedtime dosing for better overnight blood pressure control
• If you are dehydrated or volume depleted (contest prep water manipulation, a hard cut), the first dose can drop blood pressure sharply. Start low.

Key Notes:

• The mechanism fits AAS-driven hypertension better than most alternatives. Androgens increase renal sodium and water retention and activate the renin-angiotensin-aldosterone system. Blocking AT1 addresses that driver directly rather than just slowing the heart.
• PPAR-gamma partial agonism (around 25-30% of a full agonist's activity at clinical doses) gives modest improvements in insulin sensitivity, triglycerides, and adiponectin in trials. Attractive if you are running GH or MK-677 and fighting the resulting insulin resistance.
• No dry cough, because ARBs do not cause the bradykinin accumulation that ACE inhibitors do.
• Hyperkalaemia is the main laboratory risk. Blocking AT1 lowers aldosterone, which lowers potassium excretion. Risk rises with potassium supplements, potassium chloride salt substitutes, NSAIDs, existing kidney impairment, or combining with an ACE inhibitor or spironolactone. Athletes on very high potassium diets or heavy electrolyte supplementation should test rather than assume.
• Expect a small creatinine rise (commonly up to 20-30%) in the first weeks. That is a haemodynamic change in glomerular filtration pressure, not kidney injury, and it usually plateaus. A larger or continuing rise needs clinical review.
• Absolutely contraindicated in pregnancy. ARBs cause foetal renal failure and skull hypoplasia in the second and third trimesters. Stop immediately if pregnancy is possible.
• Unlike losartan, telmisartan is not uricosuric, so it will not offset the uric acid rise that comes with AAS use and dehydration.
• Stacks sensibly with a low-dose PDE5 inhibitor for additional vasodilation, and with Nebivolol if resting heart rate is also high. Three mechanisms at once needs careful titration.
• Not hormonal, not suppressive, and safe to run continuously alongside TRT or a cycle.
• Measure blood pressure properly at home: seated, back supported, feet flat, arm at heart level, after 5 minutes rest, several readings over several days. A single clinic reading tells you almost nothing about what a cycle is doing.

Bloodwork Monitoring:

• Baseline before starting: Potassium, Sodium, Creatinine, eGFR, and Urea.
• Repeat at 2-4 weeks after starting and after any dose increase, then every 3-6 months once stable.
• Potassium is the marker that matters. A result above the reference range means stopping potassium supplements and salt substitutes and getting clinician review before continuing.
• Cystatin C is the better kidney measure for muscular athletes. Creatinine is inflated by muscle mass and creatine supplementation, so a creatinine-based eGFR understates true kidney function in heavy lifters and makes the expected ARB creatinine bump look worse than it is.
• Uric Acid: worth including on cycle, since AAS and dehydration raise it independently and telmisartan will not lower it.
• Fasting Glucose, HbA1c, Fasting Insulin, and HOMA-IR if you are partly using it for the PPAR-gamma metabolic effect. Otherwise the standard glucose panel is enough.
• Triglycerides may improve modestly; track them alongside the rest of the lipid panel.
• Haematocrit is unaffected. Erythrocytosis and hypertension are separate AAS problems and each needs its own management.